Combination therapy for glioblastoma shows promising results in early-stage research

UCLA researchers have discovered that combining a vaccine developed at UCLA with other experimental therapies and FDA-approved treatments shows promise for reducing the size of advanced brain tumors. The immunotherapy, which is specifically intended to treat brain tumors, is called autologous tumor lysate-pulsed dendritic cell vaccination. It uses a portion of the patient's own brain tumor and is currently being tested in humans.

In tests in animals, the scientists found that a combination of the vaccine and two different drugs that modulate distinct aspects of the immune system was more effective at allowing T cells to attack glioblastoma than the vaccine alone. The two added drugs were a PD-1 antibody blockade, which enhanced T cell activation inside the tumor, and an called PLX3397, which reduces within the tumor.

Glioblastoma is the most common type of in adults, and one of the deadliest. More than 12,000 people will be diagnosed with the disease this year, and the five-year survival rate for patients is less than 5 percent. It has a high probability of recurring after treatment and there is no standard therapy for . The team studied the approach in mice and on tumor samples from human patients.

The findings may point scientists to a process for developing more effective combination treatments for people with glioblastoma and other immunosuppressive cancers.


Explore further

Immunotherapy, gene therapy combination shows promise against glioblastoma

More information: Joseph P. Antonios et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma, Neuro-Oncology (2017). DOI: 10.1093/neuonc/now287
Citation: Combination therapy for glioblastoma shows promising results in early-stage research (2017, January 25) retrieved 23 October 2019 from https://medicalxpress.com/news/2017-01-combination-therapy-glioblastoma-results-early-stage.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more